Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - Results from the EU-GEI study

Stephanie Menghini-Mueller, Erich Studerus, Sarah Ittig, Ulrike Heitz, Laura Egloff, Christina Andreou, Lucia R. Valmaggia, Matthew J. Kempton, Mark van der Gaag, Lieuwe de Haan, Barnaby Nelson, Neus Barrantes-Vidal, Merete Nordentoft, Stephan Ruhrmann, Gabriele Sachs, Bart P. Rutten, Jim van Os, Anita Riecher-Rossler*, Philip McGuire, Maria CalemStefania Tognin, Gemma Modinos, Eva Velthorst, Tamar C. Kraan, Daniella S. van Dam, Nadine Burger, Patrick McGorry, G. Paul Amminger, Christos Pantelis, Athena Politis, Joanne Goodall, Stefan Borgwardt, Charlotte Rapp, Renata Smieskova, Rodrigo Bressan, Ary Gadelha, Elisa Brietzke, Graccielle Asevedo, Elson Asevedo, Andre Zugman, Tecelli Dominguez-Martinez, Anna Racioppi, Paula Cristobal-Narvaez, Thomas R. Kwapil, Manel Monsonet, Mathilde Kazes, Claire Daban, Julie Bourgin, Olivier Gay, Celia Mam-Lam-Fook, EU-GEI High Risk Study Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Background: Gender differences in symptomatology in chronic schizophrenia and first episode psychosis patients have often been reported. However, little is known about gender differences in those at risk of psychotic disorders. This study investigated gender differences in symptomatology, drug use, comorbidity (i.e. substance use, affective and anxiety disorders) and global functioning in patients with an at-risk mental state (ARMS) for psychosis.

Methods: The sample consisted of 336 ARMS patients (159 women) from the prodromal work package of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI; 11 centers). Clinical symptoms, drug use, comorbidity and functioning were assessed at first presentation to an early detection center using structured interviews.

Results: In unadjusted analyses, men were found to have significantly higher rates of negative symptoms and current cannabis use while women showed higher rates of general psychopathology and more often displayed comorbid affective and anxiety disorders. No gender differences were found for global functioning. The results generally did not change when corrected for possible cofounders (e.g. cannabis use). However, most differences did not withstand correction for multiple testing.

Conclusions: Findings indicate that gender differences in symptomatology and comorbidity in ARMS are similar to those seen in overt psychosis and in healthy controls. However, observed differences are small and would only be reliably detected in studies with high statistical power. Moreover, such small effects would likely not be clinically meaningful. (C) 2019 Published by Elsevier Masson SAS.

Original languageEnglish
Pages (from-to)52-59
Number of pages8
JournalEuropean Psychiatry
Publication statusPublished - Jun 2019


  • Gender differences
  • Sex differences
  • Risk for psychosis
  • Comorbidity
  • Functioning

Cite this